Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Galera Therapeutics Inc (NQ: GRTX )

3.040 +0.090 (+3.05%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 430,615
Open 2.940
Bid (Size) 2.990 (19)
Ask (Size) 3.150 (1)
Prev. Close 2.950
Today's Range 2.910 - 3.170
52wk Range 1.120 - 3.500
Shares Outstanding 42,906,833
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer
Rucosopasem in clinical development to augment the anti-cancer efficacy of stereotactic body radiation therapy 
From Galera Therapeutics
Via GlobeNewswire
Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates
From Galera Therapeutics
Via GlobeNewswire

Performance

YTD
+105.41%
+105.41%
1 Month
+2.88%
+2.88%
3 Month
+70.79%
+70.79%
6 Month
+89.41%
+89.41%
1 Year
+90.00%
+90.00%

More News

Read More
Galera Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Galera Therapeutics
Via GlobeNewswire
Analyst Ratings for Galera Therapeutics
Via Benzinga
Where Galera Therapeutics Stands With Analysts
Via Benzinga
Galera Expands Commercial Leadership Team
From Galera Therapeutics
Via GlobeNewswire
Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Galera Therapeutics
Via GlobeNewswire
Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology
From Galera Therapeutics
Via GlobeNewswire
Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates
From Galera Therapeutics
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Galera Therapeutics Announces Pricing of Registered Direct Offering of $30 Million of Common Stock and Warrants
From Galera Therapeutics
Via GlobeNewswire
Galera Announces FDA Acceptance and Priority Review of Avasopasem NDA for Radiotherapy-Induced Severe Oral Mucositis
From Galera Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis
From Galera Therapeutics
Via GlobeNewswire
Galera to Present at Piper Sandler Annual Healthcare Conference
From Galera Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates
From Galera Therapeutics
Via GlobeNewswire
Galera Therapeutics' Avasopasem Reduces Chemo-Related Kidney Disease By 50% Versus Placebo At One-Year
Via Benzinga
Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
From Galera Therapeutics
Via GlobeNewswire
Why Golden Ocean Group Is Trading Higher By 7%; Here Are 28 Stocks Moving Premarket
Via Benzinga
Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.